King's College London

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Shaare Zedek Scientific Ltd

John Maher

Daniela Yordanova Achkova

Lynsey May Whilding

Benjamin Owen Draper

Richard Esmond Beatson

Ana Catarina Parente Pereira Puri

Yechezkel Barenholz

Alberto Gabizon

Hilary Shmeeda

Ana Catarina Parente Pereira

Alberto A Gabizon

An immunoresponsive cell, such as a T-cell expressing This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Therapeutic agents

A method for expanding a population of &#x3b3;&#x3b4; T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-&#x3b2;) under conditions in which the production of effector &#x3b3;&#x3b4; T-cells having therapeutic activity against malignant disease is favored. The use of TGF-&#x3b2; in the production of effector cells in particular V&#x3b3;9V&#x3b4;2 T-cells is also described and claimed.

&#x3b3;&#x3b4; T cell expansion procedure

Gammadelta T cell expansion procedure

The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as &#x3b3;&#x3b4; T-cells.

Liposomes co-encapsulating a bisphosphonate and an amphipathic agent

Growing community of inventors

London, United Kingdom

John Maher